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Breast cancer is the most common non-skin malignancy in women, the second most common 
cause of cancer death, and the main cause of death in women ages 45 to 55 years. An esti-
mated 1 million cases of breast cancer are diagnosed annually worldwide. Approximately 
5-10% of patients with breast cancer have distant metastases at first presentation.  
The patient came to the Clinic of oncology and radiotherapy in March 2005 for further 
treatment with the diagnosis: Carcinoma metastaticum vertebrae lumbosacralis. 
Initial treatment was included 6 cycles of chemotherapy, bisphosphonate therapy and rea-
lized radiotherapy. Tumor markers at the end of treatment: CEA 238; CA15-3: 19.6.  After 
that a radical mastectomy of the left breast with dissection of left axilla was conducted and 
pathological analysis showed poorly differentiated ductal invasive carcinoma (grade 3 ac-
cording to Nottingham Histologic Score) with immunohistochemistry findings: HER: nega-
tive, ER: negative, PR: negative or Triple negative breast cancer (TNBC). 
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Introduction 
Breast cancer is the most common non-skin malignancy 
in women, the second most common cause of cancer 
death, and the main cause of death in women ages 45 to 
55 years. An estimated 1 million cases of breast cancer 
are diagnosed annually worldwide. Approximately 
5-10% of patients with breast cancer have distant me-
tastases at first presentation. Breast cancer as a biologi-
cal and genetically heterogeneous tumor often metasta-
sizes to the bone (and other sites) so patients with bone 
metastases form the largest group of patients with me-
tastatic disease. Approximately 50% of patients with 
metastatic bone disease have clinical symptoms, and in 
4% -7% develop pathological fractures of the long 
bones. The incidence is significantly high in steroid re-
ceptor positive tumors and well-differentiated lesions. 
Recent data suggest that survival may be improved if 
disease is controlled by offering loco-regional treatment 
of the primary tumor in metastatic breast cancer. Che-
motherapy or hormone therapy is often the main treat-
ment in these patients without loco-regional treatment 
(surgery or radiotherapy) except in cases of fungation 
forms and bleeding. There are studies that have shown 
that removal of primary tumor at times leads to complete 
disappearance of metastases and improvement in surviv-
al in renal cell carcinoma patients. However, such stu-
dies have never been performed in other solid tumors. 
On the other hand, there is a strong body of evidence in 
experimental settings showing that removal of primary 
tumor allows growth of metastasis. There is lack of sim-
ilar data in humans in clinical settings. This a case report 
about a 44 years old female patient with breast cancer 
with diffuse bone metastases at first presentation. 
Case Report 
The patient came to the Clinic of oncology and radio-
therapy in March 2005 for further treatment with the 
diagnosis: Carcinoma metastaticum vertebrae lum-
bosacralis diagnosed by CT stereotactic biopsy of L5. 
The patient has done the following tests: 1. Scan of ske-
leton: metastatic deposits in spine, rib 7 and 10, manu-
brium sterni and sacrum; 2. mammography findings 
were with the presence of malignancy (20,5x13 mm) in 
left breast with package lymph nodes in the left axilla; 3. 
FNAB of the breast: was without the presence of malig-
nant cells but from the lymph node of the axilla: deposit 
of ductal invasive breast cancer. In the context of this 
patient's clinical stage was: T2N1M1 Gx (Stage. IV). [2] 
Immunohistochemical findings of metastasis in the ver-
tebra was: HER: negative; ER: 2+/3+; PGR: inconclu-
sive.  CEA=9,71 ng/ml; CA15-3: 22,2 U/ml. 
Treatment: Initial treatment 2005: 6 cycles of chemo-
therapy (AC protocol - Doxorubicin 60mg/m2 + Cyclo-
phosphamid 600mg/m2 intravenous. at 21 days) + bis-
phosphonate therapy (amp. Pamidronic acid a 90 mg, 
i.v., at 28 days) [5] + realized radiotherapy on L5, TTD 
= 30Gy, 10fr/3Gy, TCT. Tumor markers at the end of 
treatment: CEA: 2,38; CA15-3: 19.6.  After that a rad-
ical mastectomy [6] of the left breast with dissection of 
left axilla was conducted and pathological analysis 
showed poorly differentiated ductal invasive carcinoma 
that infiltrates as ragged sheets of pleomorphic cells with 
numerous mitotic figures and central areas of tumor ne-
crosis (grade 3 according to Nottingham Histologic 
Score) with immunohistochemistry findings: HER: neg-
ative, ER: negative, PGR: negative or Triple negative 
breast cancer (TNBC). 
The patient was set on hormone therapy: Tabl. Tamox-
ifen a 10 mg 2x1. In June 2007 patient is started with 
second-line hormone therapy because for the growth of 
tumor marker (CEA = 17, 7), progress of metastatic dis-
ease and menopause (Aromatase inhibitor - Tabl. Letro-
zol 1x1). November 2010 due to the progress of bony 
metastases of the thoracic spine and inability for radio-
therapy due to cumulative toxicity of spinal cords from 
previous radiotherapy to the thoracic spine, bisphospho-
nate therapy was changed. (Amp. Zolendronic acid a 
4mg i.v.)[3,4] 
Results /Follow-up: 2006-2010: The patient was in 
good general condition. Continues with intravenous 
bisphosphonate therapy for 28 days and hormone thera-
py. Ultrasonography of the breast every 6 months: nor-
mal findings. Mammography annually: normal finding. 
[1] Abdominal ultrasound every 6 months: normal find-
ings. X-rays of the lungs annually: normal findings. 
Tumor markers analysis every 6 months: in reference. 
Scan of the skeleton once a year: the appearance of me-
tastases on both shoulders and right sacroiliac articula-
tion, whole thoracic and lumbar spine (2007), left cla-
vicle (2008), the progress of the thoracic spine (2010). 
2011-2013: Good general condition. Stable metastatic 
disease. The patient is still on bisphosphonates and 
hormone therapy. Scan skeleton: Regression of bone 
metastases. Eight-year survival. 
Discussion 
Tremendous international interest has been generated in 
triple-negative breast cancer, in part because of its poor-
er overall prognosis and lack of specific targeted thera-
pies.
 
Clinical trials investigating novel treatment strate-
gies in the metastatic setting are essential to improve the 
survival of this high-risk subgroup.  
The results from published literature showed that pa-
tients with TNBC have an increased likelihood of distant 
recurrence and of death compared to women with other 
types of breast cancer. The pattern of recurrence is also 
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qualitatively different. Also, according to published lite-
rature women with TNBC experience the peak of risk of 
recurrence within 3 years of diagnosis and increased 
mortality rates for 5 years from the diagnosis. 
In our case report we have an example for 8 year surviv-
al that represents the rarest percentile of the general sur-
vival rates and also states the individuality in acceptance 
of the treatment. 
Conclusion 
Some of the patients who present with breast cancer 
already have distant metastatic disease. According to 
recent literature, these patients may benefit from resec-
tion of the breast tumor. One explanation for the effect 
of this resection is that reducing the tumor load influ-
ences metastatic growth. When metastasectomy is not 
possible, minimally invasive techniques can be used in 
selected patients for the treatment of breast cancer liver 
metastases, radiofrequency ablation (RFA) being dis-
cussed most in the literature. Results of future rando-
mized controlled trials should indicate whether surgery 
of the breast tumor truly improves survival and is there 
any differences between initially bone and parenchymal 
metastases. 
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